Find Out More
Phone Number(s): (800) 322-8615; (301) 496-5583
Phone Number(s): (800) 227-2345; (404) 329-7520
Phone number(s): (888) 232-6348
- The Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, is determining whether genes associated with risk of recurrence in women with early-stage breast cancer can be used to identify the most appropriate and effective treatments for these women.
- The Integrative Cancer Biology Program combines experimental and clinical research with mathematical modeling to gain new insights into cancer biology, prevention, diagnostics, and treatments. Multiple centers are developing breast cancer computational models.
- NCI and the National Institute of Environmental Health Sciences are jointly funding three Breast Cancer and Environment Research Centers (BCERCs) to conduct interdisciplinary research on the effects of early environmental exposures on breast development and breast cancer risk.
- The Breast Cancer Surveillance Consortium (BCSC) is a research resource for investigators assessing breast cancer screening practices and their relation to stage at diagnosis, survival, and breast cancer mortality. BCSC's Risk Calculator was developed to help health professionals estimate a woman's risk of developing invasive breast cancer.
- The Cancer Genome Atlas (TCGA) researchers are systematically identifying the major genomic changes involved in more than 20 cancers using state-of-the art genomic analysis technologies. Recent findings suggest that there are genomic similarities between breast cancer and ovarian cancer, which may help to facilitate treatments for subtypes of both cancers.
- Nine breast cancer-specific Specialized Programs of Research Excellence (SPOREs) are moving results from the laboratory to the clinical setting. The SPOREs support research on the development of novel agents, technologies, and markers for better diagnosis, prognosis, screening, prevention, and treatment of breast cancer.